Raymond James & Associates grew its stake in Pediatrix Medical Group, Inc. (NYSE:MD – Get Rating) by 115.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 190,142 shares of the company's stock after purchasing an additional 101,965 shares during the period. Raymond James & Associates owned about 0.22% of Pediatrix Medical Group worth $4,465,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Alliancebernstein L.P. boosted its stake in shares of Pediatrix Medical Group by 11.9% in the 4th quarter. Alliancebernstein L.P. now owns 7,359,083 shares of the company's stock valued at $200,241,000 after purchasing an additional 781,646 shares in the last quarter. State Street Corp boosted its stake in shares of Pediatrix Medical Group by 1.8% in the 4th quarter. State Street Corp now owns 3,211,149 shares of the company's stock valued at $87,375,000 after purchasing an additional 57,309 shares in the last quarter. Segall Bryant & Hamill LLC boosted its stake in shares of Pediatrix Medical Group by 4.4% in the 4th quarter. Segall Bryant & Hamill LLC now owns 713,477 shares of the company's stock valued at $19,412,000 after purchasing an additional 30,131 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its stake in shares of Pediatrix Medical Group by 1.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 645,063 shares of the company's stock valued at $17,552,000 after purchasing an additional 9,281 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Pediatrix Medical Group by 9.3% in the 4th quarter. Bank of America Corp DE now owns 277,271 shares of the company's stock valued at $7,544,000 after purchasing an additional 23,491 shares in the last quarter. 95.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MD has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Pediatrix Medical Group from $24.00 to $16.00 in a research note on Tuesday, May 10th. BMO Capital Markets cut their target price on shares of Pediatrix Medical Group from $25.00 to $23.00 and set a "market perform" rating on the stock in a research report on Wednesday, August 10th. Finally, Credit Suisse Group cut their target price on shares of Pediatrix Medical Group from $30.00 to $28.00 and set an "outperform" rating on the stock in a research report on Thursday, August 11th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $24.67.

Pediatrix Medical Group Stock Down 4.5 %

Pediatrix Medical Group (NYSE:MD – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.04. Pediatrix Medical Group had a net margin of 4.30% and a return on equity of 16.15%. The firm had revenue of $486.00 million during the quarter, compared to analyst estimates of $491.54 million. During the same quarter last year, the business earned $0.36 EPS. The company's revenue was up 2.7% compared to the same quarter last year. Equities analysts predict that Pediatrix Medical Group, Inc. will post 1.71 EPS for the current year.

Pediatrix Medical Group Profile

(Get Rating)

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

Read More

• Get a free copy of the StockNews.com research report on Pediatrix Medical Group (MD)
• 3 Low Beta Defensive Stocks for a Tough Market
• It Could Be a September to Remember for These 3 Stocks
• Can Roblox Reverse its Falling Bookings Amid Rising Engagements
• Peak Inflation Sets the Bottom for Brinker International Stock
• Broadcom Bounces From Institutional Bottom

Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.